Nautilus Biotechnolgy
NAUT
88 hedge funds and large institutions have $54M invested in Nautilus Biotechnolgy in 2025 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 30 reducing their positions, and 12 closing their positions.
400% more call options, than puts
Call options by funds: $25K | Put options by funds: $5K
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0% more funds holding
Funds holding: 88 → 88 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.11% less ownership
Funds ownership: 50.87% → 49.76% (-1.1%)
37% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 30
50% less capital invested
Capital invested by funds: $107M → $54M (-$53.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CGL
Clarius Group LLC
Seattle,
Washington
|
+$342K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$335K |
| 3 |
Millennium Management
New York
|
+$77.2K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$75.6K |
| 5 |
Renaissance Technologies
New York
|
+$74.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$1.02M |
| 2 |
BlackRock
New York
|
-$401K |
| 3 |
Morgan Stanley
New York
|
-$329K |
| 4 |
WC
Wexford Capital
West Palm Beach,
Florida
|
-$328K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$174K |
NAUT Hedge Fund Activity: Q1 2025 in Review
88 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q1 2025, worth a combined $54M — down 50% from $107M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new NAUT positions and 12 closed out — a net gain of 1 holder — while 19 added to existing stakes and 30 trimmed.
The largest buyer was Clarius Group LLC, adding an estimated $342K. The largest seller was Bain Capital Life Sciences Investors, cutting an estimated $1.02M.
- 88 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $54M of Nautilus Biotechnolgy stock for Q1 2025, down 50% quarter-over-quarter.
- 13 funds opened new Nautilus Biotechnolgy positions in Q1 2025 and 12 closed out, a net change of +1 holder.
- The largest Nautilus Biotechnolgy buyer in Q1 2025 was Clarius Group LLC, an estimated $342K added.
- The largest Nautilus Biotechnolgy seller in Q1 2025 was Bain Capital Life Sciences Investors, an estimated $1.02M sold.
Based on aggregated 13F filings for Q1 2025.